OncoSec Medical Incorporated

2.77-0.0400-1.42%Vol 62.83K1Y Perf 133.33%
Dec 2nd, 2022 11:24 DELAYED
BID2.75 ASK2.80
Open2.76 Previous Close2.81
Pre-Market2.74 After-Market-
 -0.07 -2.48%  - -
Target Price
10.00 
Analyst Rating
Hold 3.00
Potential %
261.01 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/100 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/100 
Income Ranking
 —    -
Price Range Ratio 52W %
0.78 
Earnings Rating
Neutral
Market Cap4.96M 
Earnings Date
21st Dec 2022
Alpha-0.03 Standard Deviation0.27
Beta1.98 

Today's Price Range

2.682.81

52W Range

2.5234.76

5 Year PE Ratio Range

-0.8000-1.10

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Buy
Performance
1 Week
-16.91%
1 Month
673.91%
3 Months
310.86%
6 Months
236.86%
1 Year
133.33%
3 Years
30.84%
5 Years
-86.47%
10 Years
-95.21%

TickerPriceChg.Chg.%
ONCS2.77-0.0400-1.42
AAPL146.49-1.8250-1.23
GOOG100.07-1.2100-1.19
MSFT252.57-2.1200-0.83
XOM110.830.02530.02
WFC45.19-1.6800-3.58
JNJ177.74-1.0000-0.56
FB196.640.99000.51
GE86.080.82000.96
JPM133.84-2.4000-1.76
 
Earnings HistoryEstimateReportedSurprise %
Q03 2022--3.52-
Q02 2022-2.42-5.49-126.86
Q01 2022--5.49-
Q03 2021-0.26-0.253.85
Q02 2021-0.22-0.37-68.18
Q01 2021-0.28-0.49-75.00
Q03 2020--0.45-
Q03 2019-1.37-1.0324.82
Earnings Per EndEstimateRevision %Trend
7/2022 QR-0.0689.83Positive
7/2022 QR-0.110.00-
7/2022 FY-0.72-10.77Negative
7/2023 FY-0.65--
Next Report Date21st Dec 2022
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume62.83K
Shares Outstanding1.79K
Shares Float22.42M
Trades Count345
Dollar Volume172.24K
Avg. Volume3.00M
Avg. Weekly Volume5.92M
Avg. Monthly Volume2.31M
Avg. Quarterly Volume783.85K

OncoSec Medical Incorporated (NASDAQ: ONCS) stock closed at 2.81 per share at the end of the most recent trading day (a -1.06% change compared to the prior day closing price) with a volume of 464.07K shares and market capitalization of 4.96M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 46 people. OncoSec Medical Incorporated CEO is Daniel J. O'Connor.

The one-year performance of OncoSec Medical Incorporated stock is 133.33%, while year-to-date (YTD) performance is 191.79%. ONCS stock has a five-year performance of -86.47%. Its 52-week range is between 2.52 and 34.76, which gives ONCS stock a 52-week price range ratio of 0.78%

OncoSec Medical Incorporated currently has a PE ratio of -0.10, a price-to-book (PB) ratio of 0.75, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -87.47%, a ROC of -118.43% and a ROE of -154.68%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from OncoSec Medical Incorporated, there were 1 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. OncoSec Medical Incorporated’s next earnings report date is 21st Dec 2022.

The consensus rating of Wall Street analysts for OncoSec Medical Incorporated is Hold (3), with a target price of $10, which is +261.01% compared to the current price. The earnings rating for OncoSec Medical Incorporated stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

OncoSec Medical Incorporated has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

OncoSec Medical Incorporated has a Neutral technical analysis rating based on Technical Indicators (ADX : 22.80, ATR14 : 0.78, CCI20 : -20.26, Chaikin Money Flow : 0.00, MACD : 0.54, Money Flow Index : 88.69, ROC : -33.10, RSI : 51.25, STOCH (14,3) : 7.29, STOCH RSI : 0.07, UO : 32.63, Williams %R : -92.71), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of OncoSec Medical Incorporated in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0 (0.00 %)
0
0
Moderate Buy
0 (0.00 %)
0
0
Hold
1 (100.00 %)
0
0
Moderate Sell
0 (0.00 %)
0
0
Strong Sell
0 (0.00 %)
0
0
Summary RatingHold
3.00
-
0.00
-
0.00

OncoSec Medical Incorporated

OncoSec Medical Inc is a healthcare sector company. It is focused on designing, developing and commercializing gene therapies, therapeutics, and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The company's lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple-negative breast cancer.

CEO: Daniel J. O'Connor

Telephone: +1 855 662-6732

Address: 3565 General Atomics Court, San Diego 92121, CA, US

Number of employees: 46

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

53%47%

Bearish Bullish

57%43%

Bearish Bullish

60%40%


News

Stocktwits